Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clearside Biomedical ( (CLSD) ) just unveiled an announcement.
On September 4, 2025, Clearside Biomedical, Inc. amended its agreements with Healthcare Royalty Partners IV, L.P., resulting in an additional $3 million payment to Clearside and adjustments to the terms of royalty payments and foreclosure rights. This amendment reflects strategic financial maneuvers to optimize Clearside’s capital structure and secure its technology assets, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (CLSD) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Underperform.
Clearside Biomedical’s overall stock score is heavily impacted by its poor financial performance and negative corporate events. The bearish technical indicators and poor valuation metrics further contribute to the low score. The company’s strategic uncertainties and risk of delisting present significant risks to investors.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. operates in the biopharmaceutical industry, focusing on developing and delivering treatments for eye diseases. The company is known for its XIPERE (triamcinolone acetonide injectable suspension) and SCS Microinjector technology, which are designed to improve the delivery of drugs to the back of the eye.
Average Trading Volume: 4,564,011
Technical Sentiment Signal: Sell
Current Market Cap: $27.16M
Find detailed analytics on CLSD stock on TipRanks’ Stock Analysis page.